Catheter-related infections, exit-site-tunnel infections and peritonitis remain the Achilles heel of peritoneal dialysis. Although the overall incidence of peritoneal-dialysis-related infectious complications has been reduced since the introduction of the Y-set and double bag system, approximately one-fifth of peritonitis episodes are associated with catheter exit-site and tunnel infections. Since its development in 1968, the Tenckhoff catheter has become one of the most widely used peritoneal catheters, and many have proposed that a number of modifications have made it a better choice. Controversies concerning the effect on exit-site infections of catheter(s) with one or two cuffs, with straight, coiled, Swan-Neck, or other modifications led to the randomized controlled studies that are reviewed in this paper. Several studies have confirmed that mupirocin, applied at the exit-site as part of regular exit-site care, reduces the risk of S. aureus exit-site and tunnel infections. Recently, the emergence on a world-wide basis of mupirocin-resistant S. aureus (MuRSA) in peritoneal dialysis patients has brought this prophylactic strategy into question. However the low frequency of resistant organisms after four years of mupirocin prophylaxis suggests that we can continue its use with annual surveillance.
Once established, exit-site infections may respond to appropriate treatment, but if not the only option may be catheter removal and replacement.
Although peritonitis risk has decreased over the past decade, mainly due to improvements in connection technology, exit-site and tunnel infections have not (1, 2). An exit-site infection that does not respond to treatment may lead to tunnel infection and to persistent peritonitis, which may require catheter removal and occasionally discontinuation of the peritoneal dialysis. Therefore it is important to be familiar with these factors that predispose to exit-site infection and to know how to prevent and to treat such infections. This review will discuss factors that predispose to catheter-related exit-site infections, techniques of exit-site care, and ways to prevent exit-site infection, with emphasis on S. aureus infections and their treatment (3, 4).
ChurchillD.N., TaylorD.W., VasS.I.Peritonitis in continuous ambulatory peritoneal dialysis (CAPD): A multicenter randomized clinical trial comparing tye Y connector disinfectant system to standard system. Perit Dial Int1989; 9: 159–63.
2.
LindbladA.S., HamiltonR.W., NovakJ.W.Complications of peritoneal catheters. In: LindbladA.S., NovakJ.W., NolphK.D., eds. Continuous ambulatory peritoneal dialysis in the USA final report of the national CAPD registry.Dordrecht: Kluwer, 1989, pp. 157–66.
3.
LupoA., TarchiniR., CancariniG., CatizoneL., CocchiR., De VecchiA.Long-term outcome in CAPD: A 10 year survey by the Italian Cooperative Peritoneal Dialysis Study Group. Am J Kidney Dis1994; 24: 826–37.
4.
GokalR., AlexanderS., AshS.Peritoneal catheters and exit-site practices toward optimum peritoneal access: 1998 update (Official report from the International Society for Peritoneal Dialysis). Perit Dial Int1998; 18: 11–33.
5.
CopleyJ.B.Prevention of peritoneal dialysis catheter-related infections. Am J Kidney Dis1987; 10: 401–7.
6.
AkyolA.M., PorteousC., BrownM.W.A Comparison of two types of catheters of CAPD. Perit Dial Int1990; 10: 63–6.
7.
NielsonP.K., HemmingsenC., FriisS.U., LadefogedJ., OlgaardK.Comparison of straight and curled Tenckhoff peritoneal dialysis catheters implanted by the subcutaneous technique: a prospective randomized study. Perit Dial Int1995; 15: 18–21.
8.
US Renal Data System 1992.Annual data report VI. Catheter related factors and peritonitis risk in CAPD patients. Am J Kidney Dis1992; 20(suppl 2): S48–54.
9.
WaradyB.A., SullivanE.K., AlexanderS.R.Lessons from the peritoneal dialysis patient database: A report of the North American Pediatric Renal Transplant Cooperative Study. Kidney Int1996; 49(suppl 53): S68–71.
10.
HondaM., LitakaK., KawaguchiH., hoshiS., AkashiS., KohsaaT.The Japanese National Registry Data in Pediatric CAPD Patients: A report of the study group of pediatric conference. Perit Dial Int1996; 16: 269–75.
11.
FavazzaA., PetriR., MontanaroD., BoscuttiG., BresakolaF., MioniG.Insertion of a straight peritoneal catheter is an arcuate subcutaneous tunnel by a tunneler: Long-term experience. Perit Dial Int1995; 15: 357–62.
12.
MitwalliA., KimD., WuG.Single-vs, double-cuff peritoneal catheters: A prospective controlled trial. In: KhannaR., NolphK., ProwantB., TwardowskiA., OreopoulosD., eds. Advances in CAPD: Proceedings of the fifth annual CAPD conference. Kansas City. Mo, February 1985, Toronto: University of Toronto Press1985: 35–40.
13.
GadallahM.F., RamdeenG., MignoneJ., PatelD., MitchellL., TatroS.Role of preoperative antibiotic prophylaxis in preventing postoperative peritonitis in newly placed peritoneal dialysis catheters. Am J Kidney Dis2000; 36: 1014–9.
14.
SwartzR., MessanaJ., StarmannB., WeberM., ReynoldsJ.Preventing S. aureus infection during chronic peritoneal dialysis. J Am Soc Nephrol1991; 2: 1085–91.
15.
LiberecT., ChmielewskiM., Lichodziejewska-NiemierkoM., RenkeM., ZadroznyD., RutkowskiB.Survival and function of Tenckhoff peritoneal catheters after surgical or percutaneous placement: One center experience. Letter. Int J Artif Organs2003; 26: 174–5.
16.
TenckhoffJ., SchechterH.A bacteriologically safe peritoneal access device. Trans Am Soc Artif Intern Organs1968; 14: 181–7.
17.
SoS.K.K., MahanJ.D.Jr., MauerS.M., SutherlandD.E.R., NevinsT.E.Hickman catheter for pediatric hemodialysis: A 3-year experience. Trans Am Soc Artif Intern Organs1984; 30: 619–23.
18.
RaafJ.H.Results from use of 826 vascular access devices in cancer patients. Cancer1985; 55: 1312–21.
19.
GolperT.A., BrierM.E., BunkeM.Risk factors for peritonitis in long-term peritoneal dialysis: The Network 9 Peritonitis and Catheter Survival Studies. Am J Kidney Dis1996; 38: 428–36.
20.
TwadowskiZ.J., NolphK.D., KhannaR., ProwantB.F., RyanL.P.The need for a “Swan-Neck” permanently bent, arcuate peritoneal dialysis catheter. Perit Dial Bull1985; 5: 219–23.
21.
LyeW.C., KourN-W, van der StraatenJ.A prospective randomized comparison of the Swan-Neck, coiled and straight Tenckhoff catheters in patients on CAPD. Perit Dial Int1996; 16(suppl 1): S333–5.
22.
EklundB.H., HonkanenE.O., KalanA.R., KyllonenL.E.Catheter configuration and outcome in CAPD: A prospective comparison of two catheters. Perit Dial Int1994; 14: 70–4.
23.
HwangT.L., HuangC.C.Comparison of Swan-Neck catheter with Tenckhoff catheter for CAPD. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications1994; 10: 203–5.
DanielssonA., BlohmeL., TraneausA., HylanderB.A prospective randomized study on the effect of a subcutaneously “buried” peritoneal dialysis catheter technique versus standard technique on the incidence of peritonitis and exit-site infection. Perit Dial Int2002: 22; 214–9.
26.
PrischlF.C., WallnerM., KalchmairH.Initial subcutaneous embedding of the peritoneal dialysis catheter - A critical appraisal of this new implantation technique. Nephrol Dial Transplant1997; 12: 1661–7.
27.
MoncriefJ.W., PopovichR.P.Presentation at the XVIII Annual CAPD Conference, Nashville, TN, February 24, 1998.
KubotaR., KanazawaM., TakahashiY., ToH., IshiguroN., TominoY.Implantation of peritoneal catheter using Moncrief technique: Aiming for fewer catheter-related complications. Perit Dial Int2001; 21(suppl 3): S205–8.
30.
TwardowskiZ.J., ProwantB.F., NicholsW.K., NolphK.D., KhannaR.Six year experience with Swan-Neck presternal peritoneal dialysis catheter. Perit Dial Int1998; 18: 598–602.
31.
ProwantB.F., WaradyB.A., NolphK.D.Peritoneal dialysis catheter exit site care: Results of an international survey. Perit Dial Int1993; 13: 149.
32.
ProwantB.F., SchmidtL.M., TwardowskiZ.J.Peritoneal dialysis catheter exit site care. Am Nephrol Nurs Assoc J1988; 15: 219.
33.
FuchsJ., GallagherM.E., Jackson BeyD.A prospective randomized study of peritoneal catheter exit site care. Dial Transplant1990; 19: 81.
34.
KeoghA.M.Complications of peritoneal dialysis: Peritonitis and exit site infections: Per Dial Int1996; 16 (suppl 1): S464–7.
35.
FairP.A.Hygiene for health. Nurs Times1994; 90: 71–2.
36.
PirainoB., BernardiniJ., SorkinM.The influence of peritoneal catheter exit-site infections on peritonitis, tunnel infections and catheter loss in patients on CAPD. Am J Kidney Dis1986; 8: 436–40.
37.
HerfrichG.B., PechanB.W., AliganiM.R., BarnardW.F., RakowskiT.A., WinchesterJ.F.Reduction of catheter complications with lateral placement. PD Bulletin1983; 3(suppl): S2–4.
VychytilA., LorenzM., SchneiderB., HorlW.H., Haag-WeberM.New strategies to prevent S. aureus infections in peritoneal dialysis patients. J Am Soc Nephrol1998; 9: 669–76.
41.
WikdahlA.M., EngmanU., StemayrB.G., SorensenJ.G.One-dose cefuroxime IV and IP reduces microbial growth in PD patients after catheter insertion. Nephrol Dial Transplant1997; 12: 157–60.
42.
Bennett-JonesD.N., MartinJ., BarrattA.J., DuffyT.J., NaishP.F., AberG.M.Prophylactic gentamicin in the prevention of early exit-site infections and peritonitis in CAPD. Adv Perit Dial1988; 4: 147–50.
43.
LyeW.C., LeeE.J.C., TanC.C.Prophylactic antibiotics in the insertion of Tenckhoff catheters. Scand J Urol Nephrol1992; 26: 177–80.
44.
MossB., SquireJ.R., TopleyE.Nose and skin carriage of Staphylococcus aureus in patients penicillin. Lancet1948; 254: 320–5.
45.
SewellC.M., ClarridgeJ., LackeC., WeinmanE.J., YoungE.J.Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. JAMA1982; 248: 1493–5.
46.
ZimmermanS.W., O' BrienM., WiedenhoeftF.A., JohnsonC.A.Staphylococcus aureus peritoneal catheter-related infections: A cause of catheter loss and peritonitis. Perit Dial Int1988; 8: 191–4.
47.
SessoR., DraibeS., CasteloA., SatoI., LemeI., BarbosaD., RamosO.Staphylococcus aureus skin carriage and development of peritonitis in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol1989; 31: 264–8.
48.
BommerJ., VergetisW., AndrassyK., HingstV., BorneffM., HuberW.Elimination of Staphylococcus aureus in hemodialysis patients. ASAIO J1995; 41: 127–31.
49.
FernandezC., GasparC., TorrellasA., VindelA., Saez-NietoJ.A., CruzetF., AguilarL.A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium oitment for eliminating nasal carriage of Staphylococcus aureus hospital personnel. J Antimicrob Chemother1995; 35: 399–408.
50.
ParrasF., GuerreroM.C., BouzaE., BlazwuezM.J., MorenoS., MenarwuezM.C., CercenadoE.Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother1995; 39: 175–9.
BloweyD.L., WaradyB.A., McFarlandK.S.The treatment of Staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients. Adv Perit Dial1994; 10: 297–9.
53.
BurkartJ.M.Significance, epidemiology, and prevention of peritoneal dialysis catheter infections. Perit Dial Int1996; 16(suppl 1): S340–6.
54.
HudsonI.R.B.The efficacy of intranasal mupirocin in the prevention of Staphylococcal infections: A review of recent experience. J Hosp Infect1994; 27: 81–98.
55.
HanevoldC.D., FisherM.C., WaltzR., BartoshS., BaluarteH.J.Effect of rifampin on Staphylococcus aureus colonization in children on chronic peritoneal dialysis. Pediatr Nephrol1995; 9: 609–11.
56.
ChowJ.W., YuV.L.Staphylococcus aureus nasal carriage in hemodialysis patients: Its role in infection and approaches to prophylaxis. Arch Intern Med1989; 149: 1258–62.
57.
HerwaldtL.A.S. aureus nasal carriage: Role in continuous ambulatory peritoneal dialysis-associated infections. Perit Dial Int1993; 13(suppl 2): S301–5.
58.
HolleyJ., BernardiniJ., PirainoB.Catheter infections in insulin-dependent diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int1991; 11: 347–50.
59.
BargmanJ.M.Nasal carriage of S. aureus in dialysis patients. Semin Dial1995; 8: 220–5.
60.
WeinsteinH.J.The relation between the nasal-staphylococcal-carrier state and the incidence of postoperative complications. N Engl J Med1959; 260: 1303–130.
61.
WhiteA.Increased infection rates in heavy nasal carriers of coagulase - positive staphylococci. Antimicrob Agents Chemother1963; 3: 667–70.
62.
MossB., SquireJ.R., TopleyE., JohnstonC.M.Nose and skin carriage of S. aureus in patients receiving penicillin. Lancet1948: 320–35.
63.
TullochL.G.Nasal carriage in staphylococcal skin infections. Br Med J1954: 912–3.
64.
PignatariA., PfallerM., HollisR., SessoR., LemeI., HerwaldtL.S. aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. J Clin Microbiol1990; 28: 1898–902.
65.
HolleyJ.L., BernardiniJ., PirainoB.Risk factors for tunnel infections in continuous peritoneal dialysis. Am J Kidney Dis1991; 18: 344–8.
66.
ZimmermanS.W., O' BrienM., WiedenhoeftF.A., JohnsonC.A.S. aureus peritoneal catheter - related infections: A cause of catheter loss and peritonitis. Perit Dial Int1988; 8: 191–4.
67.
ZimmermanS.W., JohnsonC.A., O' BrienM.Long-term survivors on peritoneal dialysis. Am J Kidney Dis1987; 10: 241–9.
68.
AbrahamG., SavinE., AyiomamitisA.Natural history of exit-site infection in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int1988; 8: 211–6.
69.
PirainoB., BermardiniJ., SorkinM.The influence of peritoneal catheter exit-site infections on peritonitis, tunnel infections, and catheter loss in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis1986; 8: 436–40.
70.
SewellC.M., ClarridgeJ., LackeC., WeinmanE.J., YoungE.J.Sraphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients. J Am Med Assoc1982; 248: 1493–5.
71.
WantenG.J.A., van OostP., SchneebergerP.M., KoolenM.I.Nasal carriage and peritonitis by S. aureus in patients on continuous ambulatory peritoneal dialysis: A prospective study. Perit Dial Int1996; 16: 352–6.
72.
SessoR., ParisioK., DalboniA., RabeloT., BarbosaD., CendorogloM., PignatariA., DraibeS., AjzenH.Effect of sodium fusidate and ofloxacin on S.aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol1994; 41: 370–6.
73.
PolepouM.F., JohnsonA.P., CooksonB.D., BeattiH., CharlettA., WoodfordN.Evaluation of disc diffusion and E test for determining the susceptibility of Staphylococcus aureus to mupirocin. J Antimicrob Chemother1998; 42: 577–83.
74.
WaiteN.M., WebsterN., LaurelM., JohnsonM., FongI.W.The efficacy of exit-site povidone-iodine ointment in the prevention of early peritoneal dialysis-related infections. Am J Kidney Dis1997; 29: 763–8.
75.
ZimakoffJ., Bangsgaard-PedersenF., BergenL., Baago-NielsenJ., DaldorphB., EspersenF., Gahrn-HansenB., HoibiN., JepsenO.B., JoffeP., KolmosH.J., KlausenM., KristoffersenK., LadefogedJ., Olesen-LarsenS., RosdahlV.T., ScheibelJ., StormB., Tofte JensenP.Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis centers in Denmark. The Danish Study Group of Peritonitis in Dialysis (DASPID). J Hosp Infect1996; 33: 289–300.
76.
PirainoB.A review of Staphylococcus aureus exit-site and tunnel infection in peritoneal dialysis patients. Am J Kidney Dis1990; 16: 89–95.
77.
Beard-PeglerM.A., GabelishC.L., StubbsE., HarbourC., RobsonJ., FalkM., BennR., VickeryA.Prevalence of peritonitis-associated coagulase-negative staphylococci on the skin of continuous ambulatory peritoneal dialysis patients. Epidemiol Infect1989; 102: 365–78.
78.
KingwatanakulP., WaradyB.A.Staphylococcus aureus nasal carriage in children receiving long-term peritoneal dialysis. Adv Perit Dial1997; 13: 281–4.
79.
Perez-FontanM., Garcia-FalconT., RosalesM., Rodriguez-CarmonaA., AdevaM., Rodriguez-LozanoI., MoncalianJ.Treatment of Staphylococcus aureus nasal carriers in continuous ambulatory peritoneal dialysis with mupirocin: Long-term results. Am J Kidney Dis1993; 22: 708–12.
80.
ZimmermanS.W., AhrensE., JohnsonC.A., CraigW., LeggetJ., O; BreinM.Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections. Am J Kidney Dis1991; 18: 225–31.
81.
PignatariA., JonesR.N., BarrettM.R., SessoR., LemeI., PfallerM.A.Use of antimicrobial susceptibility testing for epidemiology and the selection of oral, parenteral and topical regimens for control of CAPD associated S. aureus infection. J Chemother1991; 3: 108–16.
82.
BryanC.S., WilsonR.S., MeadeP., SillL.S.Topical antibiotic ointment for staphylococcal nasal carriers: Survey of current practices and comparison of bacitracin and vancomycin ointments. Infect Control1980; 1: 153–6.
83.
FaveroM.S., TokarsJ.I., ArduinoM.J., AlterM.J.Nosocomial infections associated with hemodialysis. In: MayhallC.G., ed. Hospital epidemiology and infection.Philadelphia, PA: Lippincott Williams & Wilkins, 1999, pp. 897–917.
84.
BolyardE.A., TablanO.C., WilliamsW.W., PearsonM.L., ShapiroC.N., DeitchmannS.D.Guideline for infection control in healthcare personnel. 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol1998; 19: 407–63.
85.
WardA., Campoli-RichardsD.M.Mupirocin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs1986; 32: 425–44.
86.
ParentiM.A., HatfieldS.M., LeydenJ.J.Mupiricin: A topical antibiotic with a unique structure and mechanism of action. Clin Pharm1987; 6: 761–70.
87.
HughesJ., MellowsG.Inhibition of isoleucyl-transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid. Biochem J1978; 176: 305–18.
88.
SutherlandR., BoonR.J., GriffinK.E., MastersP.J., SlocombeB., WhiteA.R.Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother1985; 27: 495–8.
89.
HudsonI.R.B.The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: A review of recent experience. J Hosp Infect1994; 27: 81–98.
90.
CasewellM.W., HillR.L.R.Elimination of nasal carriage of S.aureus with mupirocin (pseudomonic acid) - a controlled trial. J Antimicrob Chemother1986; 17: 365–72.
91.
DoebbelingB., BrenemanD., MarchR., ReaganD., WenzelR.Multi-centre study of elimination of S.aureus nasal carriage with calcium mupirocin ointment in heathy subjects. In: Proceedings of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1992; Oct 11-14, Anaheim, Abstract no. 1688.
92.
DoebbelingB.N., PfallerM.A., ReaganD.R., HoustonA.K., HollisR.J., WenzelR.P.Investigation of the epidemiology of S. aureus carriage. In: Proceedings of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy; 1991; Abstract no. 27: 103.
93.
RedheadR.J., LampY.J., RowsellR.B.The efficacy of calcium mupirocin in the eradication of nasal S.aureus carriage. Br J Clin Pharmacol1991; 45: 252–4.
94.
CedernaJ.E., TerpenningM.S., EnsbergM., BradleyS.F., KauffmanC.A.S. aureus nasal colonization in a nursing home: eradication with mupirocin. Infect Control Hosp Epidemiol1990; 11: 13–6.
95.
JimenezM.L., del ReyM.C., Henar, CarrascoN., AlarconT., Lopez-BreaM.Effect of nasal mupirocin in an outbreak of methicillin-resistant S. aureus. In: Proceedings of the 17th International Congress of Chemotherapy; 1991; Berlin. Abstract no. 998.
96.
BoelaertJ.R., Van LanduytH.W., GodardC.A.Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemia in hemodialysis patients. Nephrol Dial Transplant1993; 8: 235–9.
97.
YuV.L., GoetzA., WagenerM.Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophyl axis. N Engl J Med1986; 315: 91–6.
98.
Coles GA (Mupirocin Study Group).The effect of intranasal mupirocin on CAPD exit site infections (Abstract). J Am Soc Nephrol1994; 5: 439.
99.
BernardiniJ., LutesR., JohnstonJ.R., HolleyJ.L., PirainoB.Randomized trial of rifampin versus mupirocin to prevent S.aureus infections in PD patients (Abstract). Perit Dial Int1995; 15(suppl): S517.
100.
FallerB.New findings on the prevention of exit-site infections. European multicenter trial results. 15th Annual Conference on Peritoneal Dialysis. Baltimore, MD, 1995: 147–64.
101.
BernardiniJ., PirainoB., HolleyJ., JohnstonJ.R., LutesR.A randomized trial of S. aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis1996; 27: 695–700.
102.
ThodisE., BhaskaranS., PassadakisP., BargmanJ., VarS., OreopoulosD.Decline in S. aureus exit site infection and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site. Perit Dial Int1998; 18: 261–70.
103.
CaseyM., TaylorJ., ClinardP., GrahamA., MauckV., SpainhourL.Application of mupirocin cream at the exit-site reduces exit-infections and peritonitis in peritoneal dialysis patients. Perit Dial Int2000; 20: 566–74.
104.
UttleyL., SmartB., HutchinsonA., GokalR.Decrease in infections with the introduction of mupirocin dream at the catheter exit-site (Abstract). Perit Dial Int2001; 21(suppl 2): S86.
105.
BoerW.H.Daily nasal and exit-site mupirocin application greatly reduces the S. aureus peritonitis rates without causing mupirocin resistance. (Abstract). Perit Dial Int2001; 21(suppl 2): S122.
106.
RamosR.L., TeixeiraL.A., OrmondeL.R., SiqueiraP.L., SantosM.S., MarangoniD.Emergence of mupirocin resistance in multiresistant Staphylococcus aureus clinical isolates belonging to Brazilian epidemic clone III: B: A. J Med Microbiol1999; 48: 303–7.
107.
Netto dos SantosK.R., de Souza FonsecaL., Gontijo FilhoP.P.Emergence of high-level mupirocin resistance in methicillin-resistant S. aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol1996; 17: 813–16.
108.
VasquezJ.E., WalkerE.S., FranzusM.S., OverbayB.K., ReaganD.R., SarubbiF.A.The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veteran's Affair hospital. Infect Control Hosp Epidemiol2000; 7: 459–64.
109.
LeskiT.A., GniadkowskiM., SkoczynskaA., StefaniukE., TrzcinskiK., HryniewiczW.Outbreak of mupirocin-resistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. J Clin Microbiol1999; 37: 2781–8.
110.
NakagawaS., ImumaY., YamamotoH., NakaoM., SugiuraS., NishinoT.Detection of mupirocin resistant staphylococci from patients treated with mupirocin. Kansenshogaku Zasshi2001; 75: 7–13.
111.
CooksonB.D.The emergence of mupirocin resistance: A challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother1998; 41: 11–8.
112.
WodfordN., WatsonA.P., PatelS., JevonM., WaghornD.J., CooksonB.D.Heterogeneous location of the mupA high-level mupirocin resistance gene in Staphylococcus aureus. J Med Microbiol1998; 47: 829–35.
113.
ThomasD.G., WilsonJ.M., DayM.J., RussellA.D.Mupirocin resistance in staphylococci: Development and transfer of isoleucyl-tRNA synthetase-mediated resistance in vitro. J Appl Microbiol1999; 86: 715–22.
114.
GilbartJ., PerryC.R., SlocombeB.High-level resistance in Staphylococcus aureus: Evidence for two distinct isoleucyl-tRNA synthetases. Antimicrobiol Agents Chemother1993; 37: 32–8.
115.
AnnigeriR., ConlyJ., VasS.Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int2001; 21: 554–9.
116.
Perez-FontanM., RosalesM., Rodriguez-CarmonaA., FalconT.G., ValdesF.Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis2002; 39: 337–41.
SchmitzF.J., LindenlaufE., HofmannB., FluitA.C., VerhoefJ., HeinzH.P.The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother1998; 42: 489–95.
121.
RileyT.B., CarsonC.F., BowmanR.A., MulgraveL., GolledgeC.L., PearmanJ.W.Mupirocin-resistant methicillin-resistant Staphylococcus aureus in Western Australia. Med J Aust1994; 161: 397–8.
122.
MillerM.A., DascalA., PortnoyJ., MendelsonJ.Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol1996; 17: 811–3.
123.
Perez-FontanM., RosalesM., Rodriguez-CarmonaA., FalconT.G., ValdesF.Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis2002; 39: 337–41.
124.
VasS.I., ConlyJ., BargmanJ.M., OreopoulosD.G.Resistance to mupirocin: No indication of it to date while using mipirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients. Perit Dial Int1999; 19: 313–14.
125.
RosalesN., Perez-FontanM., Rodriguez-CarmonaA., Garcia-FalconT.Increasing resistance to mupirocin of Staphylococcus aureus (S. Au) strains isolated from peritoneal dialysis (PD) patients and their partners: Long term study (Abstract). Perit Dial Int2001; 21(suppl 2): S5128.
126.
VasquezJ.E., WalkerE.S., FranzusM.S., OverbayB.K., ReaganD.R., SarubbiF.A.The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans' Affair Hospital. Infect Control Hosp Epidemiol2000; 21: 459–64.
127.
SchmitzF.J., LindenlaufE., HofmannB., FluitA.C., VerhoefJ., HeinzH.P.The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother1998; 42: 489–95.
128.
Dos SantosK.R.N., de Souza FonsecaL., FilhoP.P.G.Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol1996; 17: 813–6.
129.
MillerM.A., DascalA., PortnoyJ., MendelsonJ.Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol1996; 17: 811–3.
130.
MatanabeH., MasakiH., AsohN., WatanabeK., OishiK., FurumotoA.Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan. J Hosp Infect2001; 47: 294–300.
131.
LuzarM.A.Exit-site infection in CAPD: A review. Contrib Nephrol1990; 85: 57–66.
132.
PollockC.A., IbelsL.S., CatersonR.J., MahonyJ.F., WaughD.A.Continuous ambulatory peritoneal dialysis: Eight years of experience at a single center. Medicine1989; 68: 293–308.
KeaneW.for the Advisory Committee on Peritoneal Dialysis Management of the IS PD. Adult peritoneal dialysis related peritonitis treatment recommendations. Update 2000; Perit Dial Int2000; 20: 442–60.
137.
RaoS.P., OreopoulosD.G.Unusual complications of a polyurethane PD catheter. Perit Dial Int1997; 17: 410–2.
138.
SuhH., WadhwaN.K., CabraldaT., BonannoJ., WasilukA., SorrentoJ.Persistent exit-site/tunnel infection and subcutaneous cuff removal in PD patients. In: KhannaR., ed. Advances in peritoneal dialysis.Toronto: Peritoneal Dialysis Publications1997; 13: 233–6.
139.
KhannaR., TwardowskiZ.J.Recommendations for treatment of exit-site pathology. Perit Dial Int1996; 16(suppl 3): S100–4.
LeheyD.J., GandhiV.C., DaugirdasJ.T.Peritonitis and exit-site infection. In: DaugirdasJ.T., IngT.S., eds. Handbook of dialysis.2nd ed. Boston: Little, Brown and Company, 1994: 338–62.
142.
KazmiH.R., RaffoneF.D., KligerA.S., FinkelsteinF.O.Pseudomonas exit-site infections in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol1992; 2: 1498–501.
143.
SzaboT., SiccionZ., IzattS., VasS., BargmanJ., OreopoulosD.G.Outcome of pseudomonas aeruginosa exit-site and tunnel infections: A single center's experience. Adv Perit Dial1999; 15: 209–12.
144.
ScalamognaD., De VecchiA., MaccanoM.Cuff-shaving procedure. A rescue treatment for exit-site infection unresponsive to medical therapy. Nephrol Dial Transplant1995; 10: 2325–7.
145.
PirainoB., BernardiniJ., PeitzmanA., SorkinM.Failure of peritoneal catheter cuff shaving to eradicate infection. Perit Dial Bull1987; 7: 179–82.
146.
LoC.V., ChuW.L., ManK.M., VingS., LeeW.L., ChuM.F., ChengS.W., LoW.K.Pseudomonas exit-site infections in CAPD patients: Evolution and outcome of treatment. Perit Dial Int1998; 18: 637–9.
147.
LassusA., ForstromS., SaloO.A double-blind comparison of sulconazole nitrite 1% cream with clotrimazole 1% cream in the treatment of dermatophytoses. Br J Dermatol1983; 108: 195–8.
